Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations ...

Some lymphomas grow and spread slowly (described as 'indolent'), for example follicular lymphoma and marginal zone lymphoma. Others are faster growing ('aggressive'), for example, diffuse large B ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

The FDA has granted a priority review to Roche's T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December. The first-in-class drug ...

Reviewed by Chaitra Ujjani, MD, Assistant Professor, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Individuals with follicular lymphoma ...

"China conditionally approves Hutchmed’s Tazverik for follicular lymphoma" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this ...